Addition of Dr. Norman LaFrance strengthen further Jubilant DraxImage
MONTREAL, Oct. 17, 2012 /PRNewswire/ - Jubilant DraxImage Inc.
(hereinafter "JDI"), a Jubilant Life Sciences Company, is pleased to
announce the appointment of Dr. Norman LaFrance as Vice President,
Medical & Regulatory Affairs and Chief Medical Officer, Jubilant
DraxImage Inc. with effect from October 16, 2012.
Dr. LaFrance has extensive and successful FDA and global clinical
regulatory and market support experience; he directed the approval of
Cardiolite®, Persantine® and Neurolite® while he worked at DuPont
Merck. He is well known at the FDA and was selected in the 4th quarter
of 2011 in a unanimous recommendation from all relevant industry trade
organizations to be the industry's representative to the FDA Medical
Imaging Advisory Committee [MIDAC]. Dr. LaFrance also led regulatory
and/or medical affairs functions while at Bracco, Celltech, Bausch &
Lomb and Molecular Insight Pharmaceuticals. Dr. LaFrance supported and
championed the RB-82 Generator while at Bracco and has well established
productive relationships throughout the nuclear and medical communities
and enjoys an excellent professional working collaboration with KOL's.
Dr. LaFrance has both Bachelor of Science and Master of Engineering
degrees in Nuclear Engineering & Science from Rensselaer Polytechnic
Institute [RPI], Troy, New York. Dr. LaFrance also has an MD degree
from the University of Arizona, College of Medicine, Tucson, AZ,
including electives at Yale University, College of Medicine, New Haven,
Connecticut and University of Nevada, College of Medicine, Reno,
Nevada. Dr. LaFrance retains active medical licensure and is double
Board Certified in both Nuclear Medicine and Internal Medicine where he
has also attained Fellowship Honors. Dr LaFrance practiced medicine
for over 10 years and he has previous experience as Clinical Director
of Nuclear Medicine at Johns Hopkins where he held faculty appointments
at Johns Hopkins School of Medicine in Radiology and Medicine and at
the Johns Hopkins School of Public Health in Radiation/Health Sciences
in addition to his appointment as Clinical Director of Nuclear Medicine
at Johns Hopkins Hospital. At Hopkins, he was also a member of the
Johns Hopkins Medical Institution's IRB and Chairman of both the RDRC
[Radioactive Drug Research Committee] and CRC [Clinical Radiation
Committee - an IRB sub-committee].
Martyn Coombs, President of Jubilant DraxImage stated, " We are very
pleased to welcome Norman, who has extensive experience in our
industry, to join the JDI team. He is a seasoned executive with an
impressive track record and I look forward to his contribution towards
the achievement of our vision. "
About Jubilant DraxImage Inc.
Jubilant DraxImage Inc., a subsidiary of Jubilant Life Sciences,
develops, manufactures and markets diagnostic and therapeutic
radiopharmaceuticals for the global nuclear medicine marketplace.
Jubilant DraxImage Inc.'s mission is to be a leading global provider of
radiopharmaceuticals and value-added enabling technologies. Products
include a proprietary line of lyophilized Technetium-99m kits (MAA,
MDP, DTPA and Sestamibi). Jubilant DraxImage Inc. is also a leading
supplier of I-131 radiopharmaceuticals in North America, used for the
diagnosis and treatment of thyroid disorder and cancer. Jubilant
DraxImage Inc. products are exported worldwide, with regulatory
approvals in USA, South America, parts of Europe and South Asia. More
information about Jubilant DraxImage is available at www.draximage.com.
SOURCE Jubilant DraxImage Inc.